BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 24086952)

  • 21. Future agents and treatment directions in multiple myeloma.
    Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
    Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
    Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
    Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
    Dolloff NG
    Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
    Lee HC; Mark TM; Shah JJ
    Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel agents in the treatment of multiple myeloma: a review about the future.
    Naymagon L; Abdul-Hay M
    J Hematol Oncol; 2016 Jun; 9(1):52. PubMed ID: 27363832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update in treatment options for multiple myeloma in nontransplant eligible patients.
    Broijl A; Sonneveld P
    Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies in myeloma.
    Sondergeld P; van de Donk NW; Richardson PG; Plesner T
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
    Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
    BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Relapsed/Refractory Multiple Myeloma.
    Neri P; Bahlis NJ; Paba-Prada C; Richardson P
    Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The therapeutic potential of microbial proteasome inhibitors.
    Momose I; Kawada M
    Int Immunopharmacol; 2016 Aug; 37():23-30. PubMed ID: 26589840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
    Grosicki S; Barchnicka A
    Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
    Xia C; Ribeiro M; Scott S; Lonial S
    Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Novel agents in multiple myeloma treatment].
    Ito S
    Rinsho Ketsueki; 2015 Oct; 56(10):2066-73. PubMed ID: 26458446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel therapeutic strategies for multiple myeloma.
    Mimura N; Hideshima T; Anderson KC
    Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple myeloma: new uses for available agents, excitement for the future.
    Anderson KC
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
    Lee HC; Weber DM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Research progress in proteasome inhibitor resistance to multiple myeloma.
    Wu J; Liu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Multiple myeloma and other plasma cell dyscrasias].
    Nagy Z
    Magy Onkol; 2016 Jun; 60(2):154-63. PubMed ID: 27275642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.